

# LME Week Asia 2025: Nickel

Metals debate: navigating the "new normal" for metal markets

Dr. Guy Wolf CFA, Marex Global Head of Market Analytics



#### LME Nickel

#### Key factors

A market that has constantly shown market consensus to be wrong

Deep in the cost curve but lacking an upside narrative?

Volumes/liquidity now fully back to pre-market closure levels


Still part of the EV narrative which has been lost in the tariff turmoil

Inventories starting to draw and spreads showing signs of life

The 'stealth' performer in 2025?




#### Market back to 'normal'





### A bear market that cannot seem to go lower

Nickel (LME) Net Specs and Fast, Medium, Slow Components






## And spreads getting tighter as stocks start to draw?


#### Recent rolls for Nickel (LME) against net specs and inventories


The first panel shows the Market Analytics Net Specs estimate in terms of lots. The second panel shows the index benchmark spread settlements with the roll period coloured gold. On the third panel, LME total inventory levels are shown, categorised by on warrant stocks (dark blue) and cancelled warrants (light blue).





## The need for EV subsidies is nearly over







This document has been prepared by Marex for information purposes only.

The Marex ® group of companies includes Marex Financial (including the Marex Solutions division), Marex Spectron International Limited, CSC Commodities UK Limited, Tangent Trading Limited, Marex Spectron Europe Limited, Marex North America LLC, Marex Capital Markets Inc., Marex Derivative Products Inc., Marex Spectron USA LLC, Spectron Energy Inc., Marex Australia Pty Ltd, Marex MENA Limited, Marex Hong Kong Limited, Marex Spectron Asia Pte. Ltd., Spectron Energy (Asia) Pte. Ltd., Marex France SAS (including the BIP AM division), X-Change Financial Access, LLC, Starsupply Petroleum Europe B.V., Volcap Trading Partners Limited, Volcap Trading Partners France SAS, Arfinco S.A, HPC SA (including its subsidiaries and branches), OTCex Hong Kong Limited and OTCex LLC (individually and collectively "Marex").

Information in this document should not be considered as advice, or as a recommendation or solicitation to purchase or otherwise deal in securities, investments or any other products. It has been prepared for institutional clients, is not directed at retail customers and does not take into account particular investment objectives, risk appetites, financial situations or needs. Recipients of this document should make their own trading or investment decisions based upon their own financial objectives and financial resources.

This document may contain forward looking statements including statements regarding our intent, belief or current expectations with respect to Marex's businesses and operations, market conditions, results of

operation and financial condition, capital adequacy, specific provisions and risk management practices. Readers are cautioned not to place undue reliance on these forward-looking statements which may be subject to change without notice. While reasonable care has been used in the preparation of forecast information, actual results may vary in a materially positive or negative manner. Forecasts and hypothetical examples are subject to uncertainty and contingencies outside Marex's control. Past performance is not a reliable indication of future performance.

The information in this document is current as at the date of publication. No part of this document may be redistributed, copied or reproduced without prior written consent of Marex. While reasonable care has been taken to ensure that the facts stated are fair, clear and not misleading, Marex does not warrant or represent (expressly or impliedly) the accuracy, completeness or fitness for purpose or use of any information in this document. Any opinions expressed may be subject to change without notice. Marex accepts no liability whatsoever for any direct, indirect or consequential loss or damage arising out of the use of all or any of the data or information in this document.

This document has been approved by Marex Financial ("MF"). MF is incorporated under the laws of England and Wales (company no. 5613061, LEI no. 5493003EETVWYSIJ5A20 and VAT registration no. GB 872 8106 13) and is authorised and regulated by the Financial Conduct Authority (FCA registration number 442767). MF's registered address is at 155 Bishopsgate, London, EC2M 3TQ.

©2023 Marex. All rights reserved.

